Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on May 25, 2018. The filing reports the appointment of a new executive officer for Napo Pharmaceuticals, Inc., a wholly-owned subsidiary of the Company. The Company is designated as an emerging growth company.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment terms.
Material Changes
The primary material change reported is the appointment of Mr. Robert J. Griffing as Chief Commercial Officer of Napo Pharmaceuticals, Inc., effective June 11, 2018. Mr. Griffing joins from Orexigen Therapeutics, Inc., where he served as Senior Vice President, Corporate Strategy.
Compensation and Terms
- Base Salary: $330,000 annually.
- Target Bonus: 40% of base salary.
- Equity Grant: Subject to Board and stockholder approval, Mr. Griffing is eligible for options to purchase 3,000,000 shares of common stock.
- Vesting Schedule: 8.3% vests three months after the start date; the remainder vests monthly over 36 months (1/36th per month).
- Severance: 12 months of base salary in the event of a change in control with elimination of job for good reason. Termination without cause results in 1 month of base pay per year of service, up to a maximum of 6 months.
- Acceleration: All outstanding awards accelerate upon termination without cause or change in control scenarios described above.
Investor Verification Checklist
- Verify the approval status of the 3,000,000 share option grant by the Board of Directors and stockholders.
- Review the full text of the Offer Letter (Exhibit 10.1) for additional covenants or conditions not summarized here.
- Confirm the impact of this appointment on the Company's cash burn rate and future operating expenses.
- Assess the strategic fit of Mr. Griffing's background in commercial operations for Napo Pharmaceuticals' pipeline.